npj Breast Cancer (Jun 2017)
The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk
- Thomas P. Slavin,
- Kara N. Maxwell,
- Jenna Lilyquist,
- Joseph Vijai,
- Susan L. Neuhausen,
- Steven N. Hart,
- Vignesh Ravichandran,
- Tinu Thomas,
- Ann Maria,
- Danylo Villano,
- Kasmintan A. Schrader,
- Raymond Moore,
- Chunling Hu,
- Bradley Wubbenhorst,
- Brandon M. Wenz,
- Kurt D’Andrea,
- Mark E. Robson,
- Paolo Peterlongo,
- Bernardo Bonanni,
- James M. Ford,
- Judy E. Garber,
- Susan M. Domchek,
- Csilla Szabo,
- Kenneth Offit,
- Katherine L. Nathanson,
- Jeffrey N. Weitzel,
- Fergus J. Couch
Affiliations
- Thomas P. Slavin
- Department of Medical Oncology, Division of Clinical Cancer Genetics
- Kara N. Maxwell
- Department of Medicine, Division of Hematology-Oncology, Perelman School of Medicine University of Pennsylvania
- Jenna Lilyquist
- Department of Health Sciences Research, Mayo Clinic
- Joseph Vijai
- Clinical Genetics Research Lab, Department of Medicine & Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center
- Susan L. Neuhausen
- Department of Population Sciences, Beckman Research Institute of City of Hope
- Steven N. Hart
- Department of Health Sciences Research, Mayo Clinic
- Vignesh Ravichandran
- Clinical Genetics Research Lab, Department of Medicine & Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center
- Tinu Thomas
- Clinical Genetics Research Lab, Department of Medicine & Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center
- Ann Maria
- Clinical Genetics Research Lab, Department of Medicine & Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center
- Danylo Villano
- Clinical Genetics Research Lab, Department of Medicine & Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center
- Kasmintan A. Schrader
- Department of Molecular Oncology, British Columbia Cancer Agency
- Raymond Moore
- Department of Health Sciences Research, Mayo Clinic
- Chunling Hu
- Department of Health Sciences Research, Mayo Clinic
- Bradley Wubbenhorst
- Department of Medicine, Division of Translational Medicine and Genetics, Perelman School of Medicine at the University of Pennsylvania
- Brandon M. Wenz
- Department of Medicine, Division of Translational Medicine and Genetics, Perelman School of Medicine at the University of Pennsylvania
- Kurt D’Andrea
- Department of Medicine, Division of Translational Medicine and Genetics, Perelman School of Medicine at the University of Pennsylvania
- Mark E. Robson
- Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center
- Paolo Peterlongo
- IFOM, the FIRC Institute of Molecular Oncology
- Bernardo Bonanni
- Division of Cancer Prevention and Genetics, European Institute of Oncology
- James M. Ford
- Division of Oncology, Stanford University School of Medicine
- Judy E. Garber
- Center for Cancer Genetics and Prevention, Dana Farber Cancer Institute
- Susan M. Domchek
- Department of Medicine, Division of Hematology-Oncology, Perelman School of Medicine University of Pennsylvania
- Csilla Szabo
- National Institutes of Health
- Kenneth Offit
- Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center
- Katherine L. Nathanson
- Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania
- Jeffrey N. Weitzel
- Department of Medical Oncology, Division of Clinical Cancer Genetics
- Fergus J. Couch
- Department of Health Sciences Research, Mayo Clinic
- DOI
- https://doi.org/10.1038/s41523-017-0024-8
- Journal volume & issue
-
Vol. 3,
no. 1
pp. 1 – 10
Abstract
Familial breast cancer: Pinning down susceptibility genes beyond BRCA Women with the heritable form of breast cancer often harbor mutations in cancer-linked genes other than the usual suspects, BRCA1 and BRCA2. Slavin, Maxwell, Lilyquist, Joseph, and colleagues from major national and international cancer centers studied 2134 women with familial breast cancer who tested negative for BRCA1/2 gene mutations. The researchers sequenced 26 known or proposed breast cancer susceptibility genes and found mutations in approximately 1 in every 12 of the study subjects. They then further broke down the susceptibility genes into those that confer high-, moderate- or low-risk—although not all the proposed breast cancer genes reached statistical significance and, as such, their clinical importance remains unclear. The results support adding some of the high- and moderate-risk genes to multi-panel diagnostic tests that aim to determine the likelihood of a women developing heritable breast cancer.